future glp-1 drugs Drugs: Where We Are and Where We're Going — Summit Re GLP-1s like Ozempic are among

The most likely explanation is a condition called telogen effluvium

FDA may still take action regarding violations of any other statutory or regulatory requirements, such as to address findings that a product may be of substandard quality or otherwise unsafe, the agency noted

Newer agents including dual and triple incretin agonists are demonstrating even greater metabolic effects in clinical trials

as a treatment for type 2 diabetes for several years, but they only recently made their way into national media headlines, largely due to their recent approval and use for weight loss

Effective July 1, 2025, AOM tirzepatide (sold as Zepbound) was removed from its standard preferred formulary ( 9 )

Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine